A novel water-soluble gossypol derivative increases chemotherapeutic sensitivity and promotes growth inhibition in colon cancer

Journal of Medicinal Chemistry

Volumn 53, Issue 15, 2010, Pages 5502-5510

  Yan, Fei ^a   Cao, Xing Xin ^c   Jiang, Hai Xia ^c   Zhao, Xiao Long ^c   Wang, Jian Yong ^a   Lin, Yi Hui ^a   Liu, Qiao Ling ^a   Zhang, Chen ^c   Jiang, Biao ^b,c   Guo, Fang ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI ADVANCED RESEARCH INSTITUTE   (China)

^c SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

6 AMINOPENICILLANIC ACID SODIUM GOSSYPOLONE; FLUOROURACIL; GOSSYPOL DERIVATIVE; PROTEIN BCL 2; PROTEIN BCL XL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; COLON CANCER; CONTROLLED STUDY; DRUG SOLUBILITY; FLUORESCENCE POLARIZATION; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; MALE; MOLECULAR MODEL; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FLUOROURACIL; GOSSYPOL; HUMANS; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; PENICILLAMINE; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; SOLUBILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; WATER;

EID: 77955348897     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1001698     Document Type: Article

References (44)

1. Qian, S. Z.; Wang, Z. G. Gossypol: A potential antifertility agent for males Annu. Rev. Pharmacol. Toxicol. 1984, 24, 329-360
2. Oliver, C. L.; Bauer, J. A.; Wolter, K. G.; Ubell, M. L.; Narayan, A.; O'Connell, K. M.; Fisher, S. G.; Wang, S.; Wu, X.; Ji, M.; Carey, T. E.; Bradford, C. R. In vitro effects of the BH3 mimetic, (?)-gossypol, on head and neck squamous cell carcinoma cells Clin. Cancer Res. 2004, 10, 7757-7763
3. Zhang, M.; Liu, H.; Tian, Z.; Griffith, B. N.; Ji, M.; Li, Q. Q. Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspase-dependent and caspase-independent cell death pathways Life Sci. 2007, 80, 767-774
4. Mohammad, R. M.; Wang, S.; Banerjee, S.; Wu, X.; Chen, J.; Sarkar, F. H. Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (?)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line Pancreas 2005, 31, 317-324
5. Zhang, M.; Liu, H.; Guo, R.; Ling, Y.; Wu, X.; Li, B.; Roller, P. P.; Wang, S.; Yang, D. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells Biochem. Pharmacol. 2003, 66, 93-103
6. Degterev, A.; Lugovskoy, A.; Cardone, M.; Mulley, B.; Wagner, G.; Mitchison, T.; Yuan, J. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL Nat. Cell Biol. 2001, 3, 173-182
7. Kitada, S.; Leone, M.; Sareth, S.; Zhai, D.; Reed, J. C.; Pellecchia, M. Discovery, characterization, and structure?activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins J. Med. Chem. 2003, 46, 4259-4264
8. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. J. Cancer statistics, 2009 CA Cancer J. Clin. 2009, 59, 225-249
9. Levin, B.; Lieberman, D. A.; McFarland, B.; Smith, R. A.; Brooks, D.; Andrews, K. S.; Dash, C.; Giardiello, F. M.; Glick, S.; Levin, T. R.; Pickhardt, P.; Rex, D. K.; Thorson, A.; Winawer, S. J. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology CA Cancer J. Clin. 2008, 58, 130-160 (Pubitemid 351830299)
10. Tsikitis, V. L.; Malireddy, K.; Green, E. A.; Christensen, B.; Whelan, R.; Hyder, J.; Marcello, P.; Larach, S.; Lauter, D.; Sargent, D. J.; Nelson, H. Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial J. Clin. Oncol. 2009, 27, 3671-3676
11. Bronner, M. P.; Culin, C.; Reed, J. C.; Furth, E. E. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model Am. J. Pathol. 1995, 146, 20-26
12. Sinicrope, F. A.; Ruan, S. B.; Cleary, K. R.; Stephens, L. C.; Lee, J. J.; Levin, B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis Cancer Res. 1995, 55, 237-241
13. Flack, M. R.; Pyle, R. G.; Mullen, N. M.; Lorenzo, B.; Wu, Y. W.; Knazek, R. A.; Nisula, B. C.; Reidenberg, M. M. Oral gossypol in the treatment of metastatic adrenal cancer J. Clin. Endocrinol. Metab. 1993, 76, 1019-1024
14. Van Poznak, C.; Seidman, A. D.; Reidenberg, M. M.; Moasser, M. M.; Sklarin, N.; Van Zee, K.; Borgen, P.; Gollub, M.; Bacotti, D.; Yao, T. J.; Bloch, R.; Ligueros, M.; Sonenberg, M.; Norton, L.; Hudis, C. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial Breast Cancer Res. Treat. 2001, 66, 239-248
15. Wang, Y.; Lei, H. P. Hepatotoxicity of gossypol in rats J. Ethnopharmacol. 1987, 20, 53-64
16. Manabe, S.; Nuber, D. C.; Lin, Y. C. Zone-specific hepatotoxicity of gossypol in perfused rat liver Toxicon 1991, 29, 787-790
17. Sakesena, S. K.; Salmonsen, R.; Lau, I. F.; Chang, M. C. Gossypol: its toxicological and endocrinological effects in male rabbits Contraception 1981, 24, 203-214
18. Chadha, S.; Sanyal, S. N.; Kanwar, U. Effects of gossypol acetic acid on the absorptive and digestive functions of rat intestine Biochem. Int. 1988, 17, 1117-1133
19. Loberg, R. D.; McGregor, N.; Ying, C.; Sargent, E.; Pienta, K. J. In vivo evaluation of AT-101 (R -(?)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration Neoplasia 2007, 9, 1030-1037
20. Kline, M. P.; Rajkumar, S. V.; Timm, M. M.; Kimlinger, T. K.; Haug, J. L.; Lust, J. A.; Greipp, P. R.; Kumar, S. R -(?)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells Exp. Hematol. 2008, 36, 568-576
21. Kitada, S.; Kress, C. L.; Krajewska, M.; Jia, L.; Pellecchia, M.; Reed, J. C. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048) Blood 2008, 111, 3211-3219
22. Mohammad, R. M.; Goustin, A. S.; Aboukameel, A.; Chen, B.; Banerjee, S.; Wang, G.; Nikolovska-Coleska, Z.; Wang, S.; Al-Katib, A. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1 Clin. Cancer Res. 2007, 13, 2226-2235
23. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005, 435, 677-681
24. Del Gaizo Moore, V.; Brown, J. R.; Certo, M.; Love, T. M.; Novina, C. D.; Letai, A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737 J. Clin. Invest. 2007, 117, 112-121
25. Wang, L.; Sloper, D. T.; Addo, S. N.; Tian, D.; Slaton, J. W.; Xing, C. WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth Cancer Res. 2008, 68, 4377-4383
26. Wei, J.; Kitada, S.; Rega, M. F.; Stebbins, J. L.; Zhai, D.; Cellitti, J.; Yuan, H.; Emdadi, A.; Dahl, R.; Zhang, Z.; Yang, L.; Reed, J. C.; Pellecchia, M. Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins J. Med. Chem. 2009, 52, 4511-4523
27. Kilic, A.; Schuchert, M. J.; Luketich, J. D.; Landreneau, R. J.; El-Hefnawy, T. Efficacy of signal pathway inhibitors alone and in combination with cisplatin varies between human non-small cell lung cancer lines J. Surg. Res. 2009, 154, 9-12
28. Sanli, U. A.; Gorumlu, G.; Erten, C.; Gul, M. K.; Cengiz, E.; Kucukzeybek, Y.; Karaca, B.; Atmaca, H.; Uzunoglu, S.; Karabulut, B.; Uslu, R. Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination Cell Biol. Int. 2009, 33, 1165-1172
29. Macoska, J. A.; Adsule, S.; Tantivejkul, K.; Wang, S.; Pienta, K. J.; Lee, C. T. ?(?)Gossypol promotes the apoptosis of bladder cancer cells in vitro Pharmacol. Res. 2008, 58, 323-331
30. Huang, H.; Cao, X. X.; Jiang, H. X. Faming Zhuanli Shenqing Gongkai Shuomingshu, People's Republic of China Patent CN 1887838A, 2007, 6 pp.
31. Jiang, H. X.; Cao, X. X.; Huang, H.; Jiang, B. An expedient route for the practical preparation of optically active (?)-gossypol Tetrahedron: Asymmetry 2007, 18, 2437-2441
32. Ionov, M.; Gordiyenko, N.; Olchowik, E.; Baram, N.; Zijaev, K.; Salakhutdinov, B.; Bryszewska, M.; Zamaraeva, M. The immobilization of gossypol derivative on N -polyvinylpyrrolidone increases its water solubility and modifies membrane-active properties J. Med. Chem. 2009, 52, 4119-4125
33. Balci, A.; Sahin, F. I.; Ekmekci, A. Gossypol induced apoptosis in the human promyelocytic leukemia cell line HL 60 Tohoku J. Exp. Med. 1999, 189, 51-57
34. Balakrishnan, K.; Wierda, W. G.; Keating, M. J.; Gandhi, V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells Blood 2008, 112, 1971-1980
35. Chauhan, D.; Velankar, M.; Brahmandam, M.; Hideshima, T.; Podar, K.; Richardson, P.; Schlossman, R.; Ghobrial, I.; Raje, N.; Munshi, N.; Anderson, K. C. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma Oncogene 2007, 26, 2374-2380
36. Tahir, S. K.; Yang, X.; Anderson, M. G.; Morgan-Lappe, S. E.; Sarthy, A. V.; Chen, J.; Warner, R. B.; Ng, S. C.; Fesik, S. W.; Elmore, S. W.; Rosenberg, S. H.; Tse, C. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737 Cancer Res. 2007, 67, 1176-1183
37. Okumura, K.; Huang, S.; Sinicrope, F. A. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737 Clin. Cancer Res. 2008, 14, 8132-8142
38. Sturm, I.; Kohne, C. H.; Wolff, G.; Petrowsky, H.; Hillebrand, T.; Hauptmann, S.; Lorenz, M.; Dorken, B.; Daniel, P. T. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases J. Clin. Oncol. 1999, 17, 1364-1374
39. Johnstone, R. W.; Ruefli, A. A.; Lowe, S. W. Apoptosis: A link between cancer genetics and chemotherapy Cell 2002, 108, 153-164
40. Trott, O.; Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading J. Comput. Chem. 2010, 31, 455-461
41. Mego, M. Telomerase inhibitors in anticancer therapy: gossypol as a potential telomerase inhibitor Bratisl. Lek. Listy 2002, 103, 378-381
42. Witham, J.; Valenti, M. R.; De-Haven-Brandon, A. K.; Vidot, S.; Eccles, S. A.; Kaye, S. B.; Richardson, A. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin Clin. Cancer Res. 2007, 13, 7191-7198
43. Li, R.; Zang, Y.; Li, C.; Patel, N. S.; Grandis, J. R.; Johnson, D. E. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway Mol. Pharmacol. 2009, 75, 1231-1239
44. Doshi, J. M.; Tian, D.; Xing, C. Structure?activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4 H -chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer J. Med. Chem. 2006, 49, 7731-7739